Selected Scientific Presentations
2014-2010
2014
International Society for Pharmacoeconomics & Outcomes Research (ISPOR)
17th Annual European Congress, Amsterdam / The Netherlands, November 08-12, 2014:
The Evaluation of Economic Methods to Assess the Social Value of Medical Interventions for Ultra-Rare Disorders (URDs).
(Plenary Presentation)
Abstract published in Value in Health 17 (7), 2014: A324.
- Presentation (197.9 KiB)
- Abstract (94.4 KiB)
Budget Impact Analysis of Drugs for Ultra-Rare Non-Oncological Diseases in Europe.
(Poster presentation)
Abstract published in Value in Health 17 (7), 2014: A525.
- Poster (606.2 KiB)
- Abstract (92.6 KiB)
Swiss Medical Board (SMB)
October / November 2014:
Pro bono contributions to the further conceptual development of the SwissHTA convergence initiative and the Swiss Medical Board (SMB)
HTA & Stakeholder Involvement – International References.
(Invited Presentation, Bern / Switzerland, November 19, 2014)
- Download (398.5 KiB)
HTA & Topic Selection / Scoping – International References.
(Invited Presentation, Bern / Switzerland, October 07, 2014)
- Download (909.8 KiB)
“Why the SMB is not good enough” – German: “Warum das Swiss Medical Board nicht genügt.”
- Download (570.5 KiB)
Rare Diseases and Orphan Drug Symposium and Orphan Drug Regulation Workshop
[Ilac Bilincini Gelistirme ve Akilci Ilac Dernegi]
Antalya / Turkey, September 13 (/14), 2014:
Interventions for Rare / Ultra-Rare Disorders and the Logic of Cost Effectiveness.
(Invited Presentation)
- Download (651.5 KiB)
11th Annual HTAi Meeting 2014
Grand Hyatt Washington, Washington, DC / USA, June 14-18, 2014:
Interventions for Ultra-Rare Disorders (URDs): How to Assess “Value for Money”?
(Oral Presentation, session on “Valuing Health – Past, Present, and Future”, Washington, DC, June 16, 2014)
Health Technology Assessment (HTA) in Switzerland: The “SwissHTA” Multi-Stakeholder Consensus.
(Oral presentation, session on “How to Improve Resource Allocation”, Washington, DC, June 16, 2014)
2013
International Society for Pharmacoeconomics & Outcomes Research (ISPOR)
16th Annual European Congress , Dublin / Ireland, November 02-06, 2013:
The Measurement of Health-Related Quality of Life: First German Findings from the Multi-Instrument Comparison (MIC) Study.
Value in Health 16 [7] (2013) A330.
European Society for Child and Adolescent Psychiatry (ESCAP)
15th International ESCAP Congress
Dublin, Ireland, July 06-10, 2013:
Attention-Deficit/Hyperactivity Disorder (ADHD):
A Longitudinal Analysis (2003-2009) of Prevalence, Health Care, and Direct Cost based upon Administrative Data from Nordbaden / Germany.
(Scientific Symposium)
- Download (2.8 MiB)
4th World Congress on Attention-Deficit/Hyperactivity Disorder (ADHD) - From Childhood to Adult Disease
Milan, Italy, June 07, 2013:
The Costs and Benefits of Attention-Deficit/Hyperactivity Disorder - An Economic View.
(Invited Plenary Presentation)
Abstract published in Attention-Deficit/Hyperactivity Disorders [ADHD] Vol. 5 (2), 2013: 113.
- Presentation (573.9 KiB)
- Abstract (227.4 KiB)
European Pricing Platform (EPP)
3rd EPP Life Sciences Forum, Montreux, Switzerland, June 05, 2013:
Europe - Problem Child or Rising Star? Outlook and Opportunities for Growth.
(Invited Keynote Presentation)
2012
International Society for Pharmacoeconomics and Outcomes Research (ISPOR)
15th Annual European Congress, Berlin, Germany, November 03-07, 2012:
Scientific Program Chair on Congress Highlights
The Swiss Health Technology Assessment (HTA) Consensus: Guiding Principles.
(Abstract) Value in Health 15 (7), 2012: A319.
- Download (877.3 KiB)
Involvement of CNS Specialists in Health Care Provision for Patients with Attention-Deficit/Hyperactivity Disorder (ADHD).
(Abstract) Value in Health 15 (7), 2012: A344.
- Download (166.2 KiB)
Health Care Utilization Research in Germany: Characterization of the Nordbaden Database.
(Abstract) Value in Health 15 (7), 2012: A303.
- Download (266.5 KiB)
9th European Conference on Health Economics (ECHE)
Zurich, Switzerland, July 18-21, 2012:
Will Progress in Applied Health Economics Depend on a New Evaluation Paradigm?
- Download (315.5 KiB)
12th International Symposium on MPS and Related Diseases
Amsterdam (Noordwijkerhout), The Netherlands, June 30, 2012:
Cost Effectiveness and Orphan Drugs.
(Invited Plenary Presentation)
Interview on Noordwijkerhout Symposium
2011
International Society for Pharmacoeconomics and Outcomes Research (ISPOR),
14th Annual European Congress, Madrid, Spain, November 05-08, 2011:
Increasing Use of Medication for Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in Germany Between 2003 and 2009.
(Abstract) Value in Health 14 (7) 2011: A300.
- Download (214.2 KiB)
The Cost Effectiveness of Clinically Proven Treatment Strategies for Attention-Deficit/Hyperactivity Disorder in Adult Patients.
(Abstract) Value in Health14 (7) 2011: A403.
- Download (212.3 KiB)
UK Adult ADHD Network (UKAAN), First European Adult ADHD Conference
Savoy Place, London, England, September 23, 2011:
ADHD across the lifespan – what are the costs to society?
- Download (1.2 MiB)
Verein für Socialpolitik, Ausschuss für Gesundheitsökonomie
Augsburg, Germany, October 16, 2010:
Michael Schlander, Munir Khan, John McKie, and Jeff Richardson:
Health-Realted Quality of Life (HRQoL) Instruments: Some Prerequisites for Their Appropriate Use in Economic Evaluation.